umeclidinium bromide/vilanterol trifenatate (TQC-3403) / Sino Biopharm - LARVOL DELTA

Efficacy and safety of TQC3403 in patients with chronic obstructive pulmonary disease (COPD): a multicenter, randomized, open-label, phase 3 equivalence trial. (PubMed, J Thorac Dis) - P=N/A | "This study aimed to evaluate the clinical equivalence between TQC3403 [the first generic umeclidinium/vilanterol (UMEC/VI) dry powder inhaler (DPI)] and ANORO®...TQC3403 demonstrated clinical equivalence to ANORO® with respect to efficacy, safety, and tolerability in patients with COPD, supporting its clinical use as an effective and well-tolerated alternative for this population. The clinical research was registered at Chinese Clinical Trial Register (Ref: ChiCTR2600120078)."

Journal • P3 data • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases